Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC): Encore

Laurence Krieger; Karim Fizazi; Neal Shore; Teuvo Tammela; Ulys Albertas; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Luz Murilo; Boris Alekseev; Iris Kuss; Marie-Aude Le Berre; Oana Petrenciuc; Amir Snapir; Toni Sarapohja; Matthew R. Smith

doi:10.1111/ajco.13540

Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC): Encore

Laurence Krieger
, Karim Fizazi
, Neal Shore
, Teuvo Tammela
, Ulys Albertas
, Egils Vjaters
, Sergey Polyakov
, Mindaugas Jievaltas
, Luz Murilo
, Boris Alekseev
, Iris Kuss
, Marie-Aude Le Berre
, Oana Petrenciuc
, Amir Snapir
, Toni Sarapohja
, Matthew R. Smith

Research output: Other conference contribution › Abstract › Scientific

Original language	English
DOIs	https://doi.org/10.1111/ajco.13540
Publication status	Published - 29 Nov 2020
Publication type	Not Eligible
Event	Anzup 2020: Mini Annual Scientific Meeting - Duration: 29 Nov 2020 → 30 Nov 2020 https://www.anzup.org.au/content.aspx?page=asm2020presentationsandprogrambook

Conference

Conference	Anzup 2020
Period	29/11/20 → 30/11/20
Internet address	https://www.anzup.org.au/content.aspx?page=asm2020presentationsandprogrambook

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/ajco.13540

Cite this

Krieger, L., Fizazi, K., Shore, N., Tammela, T., Albertas, U., Vjaters, E., Polyakov, S., Jievaltas, M., Murilo, L., Alekseev, B., Kuss, I., Le Berre, M.-A., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC): Encore. Abstract from Anzup 2020. https://doi.org/10.1111/ajco.13540

@conference{e177272b92a44f89a52062afdcee5c28,

title = "Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC): Encore",

author = "Laurence Krieger and Karim Fizazi and Neal Shore and Teuvo Tammela and Ulys Albertas and Egils Vjaters and Sergey Polyakov and Mindaugas Jievaltas and Luz Murilo and Boris Alekseev and Iris Kuss and \{Le Berre\}, Marie-Aude and Oana Petrenciuc and Amir Snapir and Toni Sarapohja and Smith, \{Matthew R.\}",

year = "2020",

month = nov,

day = "29",

doi = "10.1111/ajco.13540",

language = "English",

note = "Anzup 2020 : Mini Annual Scientific Meeting ; Conference date: 29-11-2020 Through 30-11-2020",

url = "https://www.anzup.org.au/content.aspx?page=asm2020presentationsandprogrambook",

}

Krieger, L, Fizazi, K, Shore, N, Tammela, T, Albertas, U, Vjaters, E, Polyakov, S, Jievaltas, M, Murilo, L, Alekseev, B, Kuss, I, Le Berre, M-A, Petrenciuc, O, Snapir, A, Sarapohja, T & Smith, MR 2020, 'Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC): Encore', Anzup 2020, 29/11/20 - 30/11/20. https://doi.org/10.1111/ajco.13540

TY - CONF

T1 - Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

T2 - Anzup 2020

AU - Krieger, Laurence

AU - Fizazi, Karim

AU - Shore, Neal

AU - Tammela, Teuvo

AU - Albertas, Ulys

AU - Vjaters, Egils

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Murilo, Luz

AU - Alekseev, Boris

AU - Kuss, Iris

AU - Le Berre, Marie-Aude

AU - Petrenciuc, Oana

AU - Snapir, Amir

AU - Sarapohja, Toni

AU - Smith, Matthew R.

PY - 2020/11/29

Y1 - 2020/11/29

UR - https://anzup.org.au/content.aspx?page=asm-miniasmwelcome

U2 - 10.1111/ajco.13540

DO - 10.1111/ajco.13540

M3 - Abstract

Y2 - 29 November 2020 through 30 November 2020

ER -

Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC): Encore

Conference

UN SDGs

Access to Document

Other files and links

Cite this